Neisseria Meningitidis Vaccine
AssigneeSanofi Pasteur Limited
InventorsRichard David Kensinger, JR., Steven L. Hauser
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.
Claims125
A Neisseria meningitidis vaccine composition comprising:
- a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
- b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
- c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein;
- and
- d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
- wherein the second conjugate is a population comprising double-end-linked conjugated polysaccharides and single-end-linked conjugated polysaccharides which both are attached to the carrier protein through a secondary amine, and the polysaccharides of the second conjugate have an O-acetylation level of 0.3 μmol/mg polysaccharide to 1.6 μmol/mg polysaccharide.
A Neisseria meningitidis vaccine composition comprising:
- a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
- b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
- c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein;
- and
- d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
- wherein the second conjugate is a population comprising single-end-linked conjugated polysaccharides which are attached to the carrier protein through a secondary amine, wherein the single-end-linked conjugated polysaccharides have a terminal unlinked saccharide, wherein the terminal saccharide has a primary hydroxyl or secondary amine linkage at the 7 position, or wherein the reducing end is modified with a (2-hydroxy)ethoxy or secondary amine linkage.
A Neisseria meningitidis vaccine composition comprising:
- a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
- b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
- c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein;
- and
- d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
- wherein the MenA capsular polysaccharide is attached to the carrier protein through a linker comprising a carbamate, a spacer, and an amide, wherein the spacer is between the carbamate and the amide and comprises 2-10 linear carbons, and the first conjugate has a polysaccharide to carrier protein mass ratio of 0.3 to 1.5.
A Neisseria meningitidis vaccine composition comprising:
- a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
- b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
- c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein;
- and
- d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
- wherein the MenA capsular polysaccharide is attached to the carrier protein through a linker comprising a carbamate, a spacer, and an amide, wherein the spacer is between the carbamate and the amide and comprises 2-10 linear carbons;
- and wherein the MenC, MenW-135, and MenY capsular polysaccharides are attached to the carrier protein through a secondary amine;
- and
- at least one of the conjugates has a weight average molecular weight ranging from 300 kDa to 1500 kDa.
A Neisseria meningitidis vaccine composition comprising:
- a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
- b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
- c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein;
- and
- d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
- wherein the carrier protein is tetanus toxoid;
- one or more of the first, second, third, and fourth conjugates has a weight average molecular weight ranging from 300 kDa to 1500 kDa;
- and the composition comprises less than 20% free polysaccharide by weight relative to total polysaccharide.
A Neisseria meningitidis vaccine composition comprising:
- a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
- b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
- c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein;
- and
- d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
- wherein the carrier protein is tetanus toxoid;
- one or more of the first, second, third, and fourth conjugates have a polysaccharide to carrier protein mass ratio of 0.3 to 1.5;
- and the composition comprises less than 20% free polysaccharide by weight relative to total polysaccharide.
The vaccine composition of any one of the preceding claims, wherein the first, second, third, and/or fourth conjugates are a population comprising molecules with a molecular weight in the range of 700 kDa to 1400 kDa or 800 kDa to 1300 kDa.
A Neisseria meningitidis vaccine composition comprising a conjugate of MenC capsular polysaccharide to a carrier protein, wherein the conjugate is a population comprising double-end-linked conjugated polysaccharides and single-end-linked conjugated polysaccharides which both are attached to the carrier protein through a secondary amine, and the polysaccharides of the conjugate of MenC capsular polysaccharide to the carrier protein have an O-acetylation level ranging from 0.3 μmol/mg polysaccharide to 1.6 μmol/mg polysaccharide.
The vaccine composition of any one of the preceding claims, wherein the MenC polysaccharide has a degree of O-acetylation ranging from 0.6 to 1.5 μmol/mg polysaccharide or 0.8 to 1.4 μmol/mg polysaccharide.
The vaccine composition of any one of the preceding claims, wherein the conjugate comprising MenC polysaccharide is a population comprising double-end-linked conjugated polysaccharides and single-end-linked conjugated polysaccharides.
The vaccine composition of any one of the preceding claims, wherein the conjugate comprising MenC polysaccharide comprises one or more modifications chosen from (i) a primary hydroxyl at the 7 position, (ii) a (2-hydroxy)ethoxy at the reducing end, and (iii) a conjugation to the carrier protein, wherein the modifications are present at no less than 25 nmol/mg polysaccharide.
The vaccine composition of any one of the preceding claims, comprising a conjugate of MenW-135 and/or MenY polysaccharide which comprises one or more modifications chosen from (i) a primary hydroxyl at a position of a vicinal diol in a native MenW-135 or MenY polysaccharide and (ii) a conjugation to the carrier protein, wherein the modifications are present at no less than 60 nmol/mg polysaccharide.
The vaccine composition of any one of the preceding claims, wherein the MenC polysaccharide is reduced in size by 3×-8× relative to native MenC polysaccharide.
The vaccine composition of any one of the preceding claims, comprising a conjugate of MenA capsular polysaccharide to a carrier protein having a polysaccharide to carrier protein mass ratio of 0.5 to 1.5 or 0.7 to 1.4.
The vaccine composition of any one of the preceding claims, comprising a conjugate of MenC and/or MenY capsular polysaccharide to a carrier protein having a polysaccharide to carrier protein mass ratio of 0.3 to 1.1.
The vaccine composition of any one of the preceding claims, comprising a conjugate of MenW-135 capsular polysaccharide to a carrier protein having a polysaccharide to carrier protein mass ratio of 0.3 to 1.3.
The vaccine composition any one of the preceding claims, comprising a conjugate of MenY capsular polysaccharide to a carrier protein having a polysaccharide to carrier protein mass ratio of 0.5 to 1.3.
The vaccine composition of any one of the preceding claims, wherein the composition comprises less than 20% free polysaccharide by weight.
The vaccine composition of any one of the preceding claims, wherein the polysaccharide of the MenA, MenC, MenW-135, or MenY conjugate is attached to the carrier protein through a linker.
The vaccine composition of any one of the preceding claims, wherein the polysaccharide of the MenA, MenC, MenW-135, and/or MenY conjugate is attached to the carrier protein through a linker of formula I:
- wherein PS indicates attachment to the polysaccharide and PR indicates attachment to the carrier protein.
The vaccine composition of any one of the preceding claims, wherein the polysaccharide of the MenA, MenC, MenW-135, and/or MenY conjugate is attached to the carrier protein as shown in formula II:
- PR—NH—CH2—PS (II)
- wherein PS indicates attachment to the polysaccharide and PR indicates attachment to the carrier protein.
The vaccine composition of any one of the preceding claims, wherein the carrier protein comprises or consists of recombinant exoprotein A (rEPA), diphtheria toxoid or a B-fragment of diphtheria toxin, CRM197, tetanus toxoid or a C-fragment of tetanus toxin.
The vaccine composition of any one of the preceding claims, wherein the carrier protein is tetanus toxoid.
A method of producing a conjugate of a Neisseria meningitidis capsular polysaccharide to a carrier protein, comprising:
- a) activating the polysaccharide with an activating agent that can form a carbamate linkage wherein the activating agent is present in a molar excess over the polysaccharide of 20-fold to 50-fold;
- b) partially quenching the activated polysaccharide and derivatizing the activated polysaccharide with a dihydrazide linker added at a mole ratio of 0.3 to 1.0 relative to polysaccharide repeat units, wherein the polysaccharide is derivatized at a ratio of one dihydrazide linker per 10-100 saccharide repeat units;
- c) conjugating the derivatized polysaccharide to the carrier protein by carbodiimide chemistry, wherein the polysaccharide is present at the beginning of the conjugation reaction at a weight-to-weight ratio of 3:1 to 5:1 relative to the carrier protein, thereby forming the conjugate.
A method of producing a conjugate of a Neisseria meningitidis capsular polysaccharide to a carrier protein, comprising:
- a) partially de-O-acetylating the polysaccharide by alkaline hydrolysis;
- b) activating the polysaccharide by periodate treatment, thereby converting diols to aldehydes to an extent of at least 20 nmol aldehyde per mg polysaccharide;
- c) conjugating the activated polysaccharide to the carrier protein by reductive amination, wherein the polysaccharide is present in the conjugation reaction at a weight-to-weight ratio of 1:1 to 5:1 relative to the carrier protein, thereby forming the conjugate.
A method of producing a conjugate of a Neisseria meningitidis capsular polysaccharide to a carrier protein, comprising:
- a) activating the polysaccharide by periodate treatment, thereby converting diols to aldehydes to an extent of at least 50 nmol aldehyde per mg polysaccharide;
- b) conjugating the activated polysaccharide to the carrier protein by reductive amination, wherein the polysaccharide is present in the conjugation reaction at a weight-to-weight ratio of 1:1 to 5:1 relative to the carrier protein, thereby forming the conjugate.
A method of purifying a conjugate of a Neisseria meningitidis capsular polysaccharide to a carrier protein from a mixture containing the conjugate, a salt, and free polysaccharide, comprising:
- a) contacting a hydrophobic interaction chromatography resin with the mixture, wherein the conjugate binds the resin;
- b) eluting free polysaccharide from the resin;
- and
- c) eluting the conjugate from the resin with an aqueous liquid, wherein the aqueous liquid is free of salt or contains less salt than the mixture, thereby obtaining a composition comprising purified conjugate.
A single unit dose of the vaccine composition of any one of claims 1-48 or 9495-103, comprising from 6 μg to 15 μg of each of the MenA, MenC, MenW-135, and MenY polysaccharides.
Dependencies are inferred from the claim text.